|Dr. Hervé Brailly Ph.D.||Co-Founder and Chairman of Supervisory Board||721.81k||N/A||1962|
|Mr. Yannis Morel||Exec. VP-Products Portfolio Strategy & Bus. Devel. & Member of Exec. Board||225.91k||N/A||1974|
|Mrs. Catherine Moukheibir MA, MBA||Advisor||280k||N/A||1959|
|Dr. Mondher Mahjoubi M.D.||Chairman of Exec. Board and Chief Exec. Officer||N/A||N/A||1959|
|Dr. François Romagné Ph.D.||Co Founder and Member of the Scientific Advisory Board||N/A||N/A||1964|
Innate Pharma S.A., a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company offers Lirilumab (IPH2102/BMS-986015), a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas. It is also involved in developing IPH4301, a humanized anti-MICA/B therapeutic antibody to treat oncology; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH33, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company has licensing agreements with Bristol-Myers Squibb, Novo Nordisk A/S, and the University of Genoa. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
Innate Pharma S.A.’s ISS Governance QualityScore as of March 1, 2018 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 2; Compensation: 10.